ZALAK PATEL: Open Payments
NPI 1013665280 · EAST CHICAGO, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$960 in 44 payments from 17 companies in 2025. Trend: 2023 $1,046 · 2024 $1,046 · 2025 $960
Food & beverage: $960
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 5 | $125 |
| Abbott Laboratories | 5 | $114 |
| AstraZeneca Pharmaceuticals LP | 5 | $95 |
| SCPHARMACEUTICALS INC. | 3 | $89 |
| Amgen Inc. | 4 | $78 |
| Novo Nordisk Inc | 3 | $69 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $64 |
| Alnylam Pharmaceuticals Inc. | 2 | $56 |
| PFIZER INC. | 3 | $53 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $38 |
Products named: LEQVIO, FARXIGA, FUROSCIX, REPATHA, Wegovy, CARDIOMEMS, Kerendia, JARDIANCE.
Industry payments across IN — which companies pay providers there.
